These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 8497456

  • 1. Ciprofibrate--a profile.
    Betteridge DJ.
    Postgrad Med J; 1993; 69 Suppl 1():S42-7; discussion S47-9. PubMed ID: 8497456
    [Abstract] [Full Text] [Related]

  • 2. [Effectiveness of ciprofibrate. Open study in a Portuguese population].
    Silva JM, Branco MC, Pereira M, Figueiredo H, Jesus LC, de Moura JP, Ferreira MR, Serra e Silva P.
    Rev Port Cardiol; 1995 Apr; 14(4):313-22, 284. PubMed ID: 7612280
    [Abstract] [Full Text] [Related]

  • 3. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M.
    Am J Ther; 2007 Apr; 14(2):213-20. PubMed ID: 17414592
    [Abstract] [Full Text] [Related]

  • 4. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
    Mikhailidis DP, Ganotakis ES, Spyropoulos KA, Jagroop IA, Byrne DJ, Winder AF.
    Int Angiol; 1998 Dec; 17(4):225-33. PubMed ID: 10204653
    [Abstract] [Full Text] [Related]

  • 5. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
    Kovács I, Tarján J, Császár A.
    Orv Hetil; 2001 Apr 15; 142(15):775-9. PubMed ID: 11367862
    [Abstract] [Full Text] [Related]

  • 6. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
    Dobiásová M, Frohlich J.
    Vnitr Lek; 2000 Mar 15; 46(3):152-6. PubMed ID: 11048517
    [Abstract] [Full Text] [Related]

  • 7. Homocysteine elevation with fibrates: is it a class effect?
    Harats D, Yodfat O, Doolman R, Gavendo S, Marko D, Shaish A, Sela BA.
    Isr Med Assoc J; 2001 Apr 15; 3(4):243-6. PubMed ID: 11344833
    [Abstract] [Full Text] [Related]

  • 8. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M, de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C, Princen HM, Kooistra T.
    Thromb Haemost; 1997 Oct 15; 78(4):1167-72. PubMed ID: 9364979
    [Abstract] [Full Text] [Related]

  • 9. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS, Kashyap ML.
    Pharmacotherapy; 2004 Dec 15; 24(12):1692-713. PubMed ID: 15585439
    [Abstract] [Full Text] [Related]

  • 10. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.
    J Cardiovasc Pharmacol; 2008 Apr 15; 51(4):331-51. PubMed ID: 18427276
    [Abstract] [Full Text] [Related]

  • 11. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P, Scheuermann E, Lang W.
    Proc Eur Dial Transplant Assoc; 1981 Apr 15; 18():169-75. PubMed ID: 7036147
    [Abstract] [Full Text] [Related]

  • 12. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C, Olsson AG.
    Int J Clin Pract Suppl; 2002 Jul 15; (130):27-32. PubMed ID: 12296606
    [Abstract] [Full Text] [Related]

  • 13. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R, Mahajan M, Singh B, Bal BS, Kant R.
    J Indian Med Assoc; 2006 Sep 15; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [Abstract] [Full Text] [Related]

  • 14. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
    Visnegarwala F, Maldonado M, Sajja P, Minihan JL, Rodriguez-Barradas MC, Ong O, Lahart CJ, Hasan MQ, Balasubramanyam A, White AC.
    J Infect; 2004 Nov 15; 49(4):283-90. PubMed ID: 15474625
    [Abstract] [Full Text] [Related]

  • 15. [Safety of ciprofibrate. Open study in a Portuguese population].
    Branco MC, de Moura JP, Pereira M, Jesus LC, Ferraz A, Silva JM, Ferreira MR, Serra e Silva P.
    Rev Port Cardiol; 1995 May 15; 14(5):395-9, 360. PubMed ID: 7654400
    [Abstract] [Full Text] [Related]

  • 16. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M.
    J Cardiovasc Pharmacol Ther; 2002 Oct 15; 7(4):219-26. PubMed ID: 12490967
    [Abstract] [Full Text] [Related]

  • 17. [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
    Zeman M, Zák A, Vecka M, Romaniv S.
    Cas Lek Cesk; 2003 Aug 15; 142(8):500-4. PubMed ID: 14626567
    [Abstract] [Full Text] [Related]

  • 18. [Ciprofibrate in the treatment of combined hyperlipoproteinemia. Results in more than 600 patients from 23 centers in the Czech Republic].
    Ceska R, Kvasnicka T, Haas T, Soska V, Vaverková H.
    Vnitr Lek; 2000 Mar 15; 46(3):157-60. PubMed ID: 11048518
    [Abstract] [Full Text] [Related]

  • 19. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
    dos Santos JE, Loures-Vale AA, Novazzi JP, Rabelo LM, Martinez TL.
    Arq Bras Cardiol; 1996 Dec 15; 67(6):419-22. PubMed ID: 9246832
    [Abstract] [Full Text] [Related]

  • 20. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun 15; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.